↑ 薬物リストへ　← 戻る

Abbv-8e12    (DrugBank: -)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
5進行性核上性麻痺9
7大脳皮質基底核変性症1

5. 進行性核上性麻痺　［臨床試験数：82，薬物数：107（DrugBank：36），標的遺伝子数：60，標的パスウェイ数：90］
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 82 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2017-001590-16-DE
(EUCTR)		02/07/201911/01/2019An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Progressive Supranuclear Palsy (PSP)
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12		AbbVie DeutschlandNULLNot RecruitingFemale: yes
Male: yes		330Phase 2United States;Canada;Australia;Germany
2EUCTR2016-001635-12-ES
(EUCTR)		04/07/201810/05/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12
Other descriptive name: ABBV-8E12		AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes		330Phase 2United States;Canada;Spain;Australia;Germany;Italy
3EUCTR2017-001590-16-IT
(EUCTR)		27/04/201804/11/2020An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) - na Progressive Supranuclear Palsy (PSP)
MedDRA version: 21.1;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: na
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12		ABBVIE DEUTSCHLAND GMBH & CO. KGNULLNot RecruitingFemale: yes
Male: yes		180Phase 2United States;Canada;Australia;Germany;Italy
4NCT03413319
(ClinicalTrials.gov)		April 17, 201823/1/2018Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNULLCompleted18 YearsN/AAll3Phase 1United States
5NCT03391765
(ClinicalTrials.gov)		January 24, 20182/1/2018An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsy (PSP)Drug: ABBV-8E12AbbVieNULLCompleted40 YearsN/AAll143Phase 2United States;Australia;Canada;Italy;Japan;France
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2016-001635-12-DE
(EUCTR)		23/11/201720/02/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: ABBV-8E12
Product Code: ABBV-8E12
Other descriptive name: ABBV-8E12		AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes		330Phase 2United States;Canada;Spain;Australia;Germany;Italy
7EUCTR2016-001635-12-FR
(EUCTR)		26/10/201717/07/2017A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: ABBV-8E12AbbVie Deutschland GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes		180Phase 2United States;France;Canada;Spain;Australia;Germany;Italy
8EUCTR2016-001635-12-IT
(EUCTR)		31/05/201705/02/2018A Study to Evaluate the Efficacy, Safety , Tolerability and Pharmacokinetics of ABBV-8E12 in Subjects with Progressive Supranuclear Palsy.A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - NA Progressive Supranuclear Palsy
MedDRA version: 20.0;Level: PT;Classification code 10036813;Term: Progressive supranuclear palsy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: ABBV-8E12
Product Code: ABBV-8E12
INN or Proposed INN: ABBV-8E12		ABBVIE DEUTSCHLAND GMBH & CO. KGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		180Phase 2United States;Canada;Australia;Italy
9NCT02985879
(ClinicalTrials.gov)		December 12, 20161/12/2016A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: placebo;Drug: ABBV-8E12AbbVieNULLCompleted40 YearsN/AAll378Phase 2United States;Australia;Canada;France;Germany;Italy;Japan;Spain

先頭へ


7. 大脳皮質基底核変性症　［臨床試験数：16，薬物数：33（DrugBank：11），標的遺伝子数：6，標的パスウェイ数：13］
Searched query = "Corticobasal degeneration", "Corticobasal syndrome", "CBD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 16 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03744546
(ClinicalTrials.gov)		November 26, 201814/11/2018Expanded Access to ABBV-8E12Expanded Access to ABBV-8E12Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)Drug: ABBV-8E12AbbVieNULLNo longer available40 YearsN/AAllNULL

先頭へ